Kyle W. Sloop: The Scientist Who Explained Why Tirzepatide Works
Kyle W. Sloop
the scientist who explained
why tirzepatide works
From an evening PhD program in Indianapolis to corresponding authorship on the papers that decoded tirzepatide's receptor pharmacology — and then helped move GLP‑1 medicine from the needle to the pill.
When tirzepatide outperformed selective GLP‑1 drugs in early clinical trials, the obvious question inside Eli Lilly's research labs was not whether the molecule worked, but why it worked so much better than the sum of its two receptor targets. Answering that question — in exacting pharmacological and, later, atomic-resolution structural detail — became the defining scientific contribution of Kyle W. Sloop, a Lilly Research Laboratories scientist whose career began not in an elite doctoral program but on the bench floor of the company itself, as an associate scientist who took graduate classes at night.
An associate scientist who did graduate school after work
Kyle Sloop grew up in Greenwood, Indiana, a suburb just south of Indianapolis, and stayed close to home for his undergraduate years, earning a bachelor's degree in biology at Indiana University Bloomington. What followed was not the conventional straight line into a PhD program. Sloop went to work at Eli Lilly and Company as an associate scientist, and it was while holding down that day job that he began taking evening graduate-level classes at the School of Science at what was then Indiana University-Purdue University Indianapolis (IUPUI).
He has said the appeal of that program was its research orientation: a curriculum built around real hypothesis-testing rather than coursework for its own sake, which suited someone already embedded in an industrial research environment and looking to deepen, rather than pause, that work. Sloop completed his Ph.D. in molecular biology and biochemistry at IUPUI in 2001, while continuing at Lilly throughout. His own advice to students since has been to choose a mentor and a lab that fits one's own scientific philosophy and personality as much as its subject matter — advice that reads, in hindsight, like a description of the unusually long, single-employer research career that followed.
It is worth placing that path in context. The 1990s, when Sloop was starting out as an associate scientist, were the years in which Indianapolis's status as a biotechnology hub was being built in real time, largely around Lilly's own recombinant-insulin and endocrine research programs — the same institutional environment in which Richard DiMarchi was, at that very moment, proving that a re-engineered human insulin analog could outperform the natural hormone. An associate scientist working in that environment was not on the periphery of the industry's most consequential biology; he was inside the building where it was happening, running assays and gathering data years before earning the credential that would let him lead his own research questions. The IUPUI evening program gave him a route to that credential without requiring him to leave the environment that was already teaching him the field.
That kind of career path has become less common as pharmaceutical R&D has professionalized around credentialed entry points — postdoctoral fellowships, competitive academic placements, formal industry rotational programs. Sloop's own advice to later students, to weigh a lab's philosophy and personality as heavily as its subject matter, reads as advice earned from having built a research identity somewhat outside that standard pipeline, inside a company lab rather than a university one, years before his name would appear as corresponding author on the papers that mattered most.
Rising through Lilly's incretin biology group
By the mid-2010s, Sloop had become a Research Advisor in the Endocrine Discovery Division of Lilly Research Laboratories, working inside the same broad diabetes and metabolic disease research organization that had, years earlier, employed peptide chemist Richard DiMarchi and would go on to develop tirzepatide's clinical program under DiMarchi's former student, John Mayer. Where DiMarchi's contribution was upstream — designing the co-agonist peptide backbone itself — Sloop's growing role sat downstream and in parallel: understanding, at the level of receptor biology and cell signaling, exactly what a candidate molecule did once it reached its target.
That distinction matters more than it might first appear. A peptide can be synthesized, purified, and dosed into an animal or a patient long before anyone fully understands its mechanism of action at the molecular level. Sloop's group specialized in closing that gap — running the receptor-binding assays, the cell-signaling pathway analyses, and eventually the structural biology that could explain not just that a molecule worked, but precisely how, and why one candidate outperformed another with an apparently similar design. His institutional affiliation today, listed on his most recent papers, is the Diabetes, Obesity and Complications therapeutic area within Lilly Research Laboratories in Indianapolis — the group at the center of the company's incretin-based drug discovery effort.
- Current groupDiabetes, Obesity and Complications, Lilly Research Laboratories, Indianapolis
- Publication record136 research works, more than 7,000 citations
- Notable collaboratorsBrian K. Kobilka (2012 Nobel Laureate, Chemistry); Jonathan Campbell and David D'Alessio, Duke University; Mette Rosenkilde, University of Copenhagen
- ORCID0000-0001-6748-9929
"Imbalanced and biased": explaining why tirzepatide outperforms
The paper that best defines Sloop's scientific contribution to tirzepatide is not a clinical trial report but a mechanistic one: a 2020 study in JCI Insight, with Sloop as corresponding author, titled "Tirzepatide is an imbalanced and biased dual GIP and GLP‑1 receptor agonist." Its central finding is easy to summarize and genuinely important to understand, because it explains something clinicians had already observed but could not yet fully account for — that tirzepatide's benefits exceeded what a simple combination of GIP and GLP‑1 activity would predict.
"Imbalanced" describes the fact that tirzepatide does not activate its two receptor targets equally. Relative to the native hormones themselves, the molecule was engineered with different potency and efficacy at the GIP receptor than at the GLP‑1 receptor — a deliberate asymmetry rather than a flaw. "Biased" describes something more subtle still: at the GLP‑1 receptor specifically, tirzepatide favors certain intracellular signaling pathways, such as cAMP generation, over others, such as beta-arrestin recruitment, a process ordinarily associated with receptor desensitization and internalization. A molecule that preferentially drives the signaling pathway linked to insulin secretion, while comparatively sparing the pathway that would blunt the receptor's ongoing responsiveness, can produce a sustained pharmacological effect that a "balanced" or unbiased agonist would not.
Put simply: tirzepatide's advantage over earlier GLP‑1-only drugs was not just that it added a second hormone's activity, but that both the ratio between the two receptor activities and the internal signaling character of that activity were tuned — whether by original design or by fortunate discovery — in a specific, non-obvious combination. Sloop's paper, produced in collaboration with academic researchers at Duke University and the University of Copenhagen who study incretin physiology independently of Lilly, gave that combination a rigorous pharmacological description for the first time, turning an empirical clinical observation into a mechanistic explanation other scientists could build on.
The distinction between "unbiased" and "biased" agonism had been a subject of academic GPCR pharmacology for years before tirzepatide, largely in the context of opioid receptors, where researchers hoped biased compounds might separate a drug's pain-relieving effects from its respiratory-depression risks by favoring one signaling pathway over another. Sloop's paper was among the first to apply that same rigorous framework to an approved-track metabolic drug, treating tirzepatide not as a black box that happened to work well in trials, but as a case study in how deliberately shaping a ligand's signaling profile — not just its binding affinity — could be a legitimate design target in its own right.
The practical implication for drug discovery was significant: it meant that two molecules with near-identical binding affinity for the same two receptors could nonetheless produce meaningfully different clinical effects, depending on which downstream signaling pathways each one preferentially activated once bound. That insight reframed how Lilly's own discovery teams, and outside academic groups, would evaluate the next generation of incretin-receptor candidates — shifting part of the evaluation from simple binding and potency assays toward more elaborate signaling-bias profiling earlier in a molecule's development, before it ever reached a clinical trial.
A cryo-EM partnership with a Nobel laureate
Explaining pharmacology through binding and signaling assays is one level of proof; seeing the physical structure of a receptor as it activates is another, and it is the level Sloop's group pursued next. In 2020, Sloop was senior author on a structural biology paper in the Proceedings of the National Academy of Sciences, describing the structural basis for GLP‑1 receptor activation by an early orally active nonpeptide agonist, LY3502970. The work used cryo-electron microscopy to visualize, at near-atomic resolution, exactly how a small, drug-like molecule — radically different in size and shape from the native 30-plus-amino-acid GLP‑1 hormone — could nonetheless dock into the receptor's binding pocket and trigger the same activating conformational change.
The collaboration brought together Lilly's discovery pharmacology group with the structural biology lab of Brian K. Kobilka, the Stanford researcher who shared the 2012 Nobel Prize in Chemistry for work on G-protein-coupled receptors — the broad family of cell-surface receptors that includes GLP‑1R and GIPR. Kobilka's methods for capturing GPCRs in their active, signaling-competent state were essential to resolving how a nonpeptide compound, docking through a different set of molecular contacts than the natural hormone, could still switch the receptor fully "on."
Why size matters
GLP-1 is a peptide of roughly 30 amino acids; a nonpeptide agonist can be a fraction of that size, small enough to survive digestion and be taken as a pill rather than injected — if it can still fit and activate the same receptor pocket.
What cryo-EM shows
Cryo-electron microscopy freezes receptor-ligand complexes and images them at near-atomic resolution, revealing which specific amino acids a drug candidate touches inside the receptor — information invisible to binding-affinity assays alone.
The 2020 PNAS structure resolved a question that had shadowed oral GLP‑1 drug discovery for years: whether a small molecule could actually reach and activate the same deep, narrow orthosteric pocket the native peptide hormone uses, or whether it would need an entirely different binding site to work at all. Some earlier experimental nonpeptide GLP‑1R compounds, including one studied by Novo Nordisk, had shown that alternate binding sites were possible; Sloop and his co-authors' structure demonstrated that LY3502970 instead threaded into the same orthosteric pocket as the natural hormone, engaging many of the same receptor residues along a different, more compact molecular path. That finding gave Lilly's medicinal chemists a validated structural template to optimize against, rather than a hypothesis to keep testing blind — a meaningful acceleration for a chemical series that would, several structural refinements later, become orforglipron.
Orforglipron and the pharmacological basis for a nonpeptide pill
That 2020 structural groundwork fed directly into Lilly's most closely watched pipeline candidate of the mid-2020s: orforglipron, an investigational once-daily oral GLP‑1 receptor agonist. In December 2024, Sloop published, as corresponding author in Science Translational Medicine, "The pharmacological basis for nonpeptide agonism of the GLP‑1 receptor by orforglipron," a study explaining in mechanistic detail how a small-molecule pill could activate the same receptor as an injectable peptide hormone, and do so efficiently.
The paper's finding, as Sloop described it publicly, was that orforglipron binds the same general pocket within the GLP‑1 receptor that the natural hormone uses, but makes contact through a different subset of amino acids inside that pocket — and that despite this different mode of engagement, the resulting interactions are efficient enough to fully activate the receptor. In laboratory experiments using engineered cells expressing the human GLP‑1 receptor, orforglipron strongly stimulated cAMP generation through the receptor's primary signaling pathway, without triggering beta-arrestin recruitment — a biased signaling profile similar in spirit to what Sloop's earlier tirzepatide paper had described, and one that may help sustain the receptor's responsiveness over time while limiting certain side effects associated with fuller, unbiased receptor activation.
The clinical stakes of that structural insight are substantial. Phase 2 data published in 2023 showed people taking orforglipron once daily achieved average body weight reductions of up to roughly 15 percent, broadly comparable to injectable semaglutide, and by 2025 Lilly was reporting Phase 3 results across multiple trials in both type 2 diabetes and obesity. An oral GLP‑1 medicine removes the cold-chain storage, injection training, and needle aversion that limit access to peptide-based drugs like tirzepatide and semaglutide — meaning the molecular-level question Sloop's structural papers answered has a very direct bearing on how many more patients, in how many more parts of the world, might eventually be able to take a GLP‑1 therapy at all.
Speaking to reporters about the finding, Sloop described the efficiency of orforglipron's binding interactions in plain terms — the molecule's contacts within the receptor pocket are efficient enough, on their own, to activate the receptor fully, without needing the broader contact surface a full-length peptide provides. That is a nontrivial pharmacological outcome: smaller molecules generally make fewer contacts with a target protein than larger ones, and fewer contacts often mean weaker or less complete activation. Demonstrating that a compact, orally bioavailable molecule could still deliver strong receptor engagement was, in effect, the structural proof that an oral GLP‑1 drug could plausibly compete with an injectable one on efficacy rather than merely on convenience.
By 2025, orforglipron sat at the center of a broader industry race toward oral incretin therapy, with Pfizer and other competitors pursuing their own small-molecule GLP‑1 candidates through different chemical strategies. Lilly's own trial program expanded well beyond the original diabetes and weight-loss indications during this period, with studies underway examining orforglipron's effects on hypertension in people with obesity and its cardiovascular outcomes in patients with atherosclerotic disease or chronic kidney disease — trials whose scientific rationale rests, at bottom, on the same receptor-level story Sloop's papers had already told: that this small molecule genuinely does what the injectable hormone does, just delivered differently.
A wider map of metabolic receptor biology
Sloop's published output extends well beyond the two molecules most associated with his name. His group has worked on long-acting glucagon receptor agonists, including a compound known as IUB288, studied for its potential to enhance weight loss when combined with bile-acid-binding resins — a reminder that glucagon receptor biology, once viewed almost entirely as a diabetes risk to be suppressed, has become its own target for metabolic benefit, a research thread that connects back to the co-agonist logic pioneered academically by Richard DiMarchi a few miles away in Bloomington.
More recent work from Sloop's group has pushed into GIP receptor biology in the brain, examining how GIP receptor agonism and antagonism produce body-weight and food-intake effects through distinct neural circuits, including GABAergic GIP-receptor-expressing neurons in the brainstem's dorsal vagal complex. Using single-nucleus RNA sequencing, the group has shown that GIP receptor antagonism, somewhat counterintuitively, produces signaling effects in the brain that closely resemble GLP‑1 receptor activation — a finding relevant to Lilly's broader incretin portfolio, since some experimental obesity drugs pair GLP‑1 agonism with GIP receptor blockade rather than GIP agonism, a strategy that appears superficially contradictory to tirzepatide's own dual-agonist design but may work through an overlapping downstream mechanism.
Taken together, this body of work — 136 papers and counting, cited more than 7,000 times — represents one of the more complete pharmacological maps of how the gut-brain hormone axis can be manipulated for metabolic benefit, built consistently from the receptor outward rather than from the clinic backward.
The mechanist behind the molecule
Richard DiMarchi's academic lab supplied the founding architectural idea for a unimolecular dual agonist. Lilly's clinical and chemistry teams, including DiMarchi's former student John Mayer, turned that idea into a dosable, manufacturable, trial-ready drug. Kyle Sloop's distinct and essential contribution sits between those two achievements and extends beyond them: explaining, with pharmacological and then structural rigor, exactly why the resulting molecule behaved the way it did — and then applying that same explanatory discipline to the next generation of oral, nonpeptide successors.
It is, in its way, a less visible kind of contribution than inventing a drug's core design or running its pivotal trial, and Sloop's public profile reflects that: no popular press profiles, no named professorship, no induction into a hall of fame, at least not yet. What exists instead is a corresponding-author's paper trail across the journals where GPCR pharmacologists actually read each other's work — JCI Insight, PNAS, Science Translational Medicine — each one answering a version of the same question that has structured his career since his evening classes at IUPUI: not simply whether a molecule works, but precisely how, and why, at the level of a single receptor's changing shape.
What the bench-first path made possible
There is a version of the tirzepatide story told entirely through chemistry: a peptide backbone re-engineered to speak to two receptors at once. Sloop's career is a reminder that the story is incomplete without pharmacology — without someone willing to sit with a molecule that already works clinically and refuse to accept "it works" as a final answer. His papers exist because that question was asked twice: once for the peptide that reached patients as Mounjaro and Zepbound, and again, years later, for the pill that may eventually replace the needle for millions of people who never wanted one in the first place.
It is a career built less on a single eureka moment than on a habit of explanation, sustained across two decades inside the same research organization he joined as an associate scientist taking night classes — proof that some of the most consequential work behind a landmark medicine happens not in its invention, but in the patient, structural work of understanding exactly why it was ever going to succeed.
The three institutions at the center of this era of metabolic medicine — Richard DiMarchi's academic lab, Lilly's clinical and chemistry teams, and Kyle Sloop's receptor pharmacology group — rarely appear together in the public account of tirzepatide's arrival, which tends to compress everything before FDA approval into a single word: discovery. Sloop's paper trail is a useful corrective to that compression. It shows discovery as a longer, more distributed process, in which understanding a drug well enough to explain it is itself a form of invention — one that made the next molecule, the pill instead of the pen, possible in turn.
Comments
Post a Comment